MedTrace Logo

a Phase 1b/2a Study of JMT202 Injection in Participants With Hypertriglyceridemia

NCT07140809 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2025-12-30

No results posted yet for this study

Summary

To evaluate the safety and tolerability of multiple subcutaneous injections of JMT202 injection in Chinese participants with hypertriglyceridemia

Conditions

  • Hypertriglyceridemia

Interventions

BIOLOGICAL

JMT202 injection

Subcutaneous injection

OTHER

Placebo

Matching Placebo

Sponsors & Collaborators

  • Shanghai JMT-Bio Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-09
Primary Completion
2026-07-31
Completion
2026-10-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07140809 on ClinicalTrials.gov